Follow-up to Merchavia: Did CDX really move from regulatory approval to commercial scale?

This Is No Longer Just About Approval. It Is About Adoption

The main article already made the broader point: CDX has become the core value driver inside Merchavia’s portfolio. This follow-up isolates the narrower question that now matters more: did late 2025 already move CDX into commercial scale, or did it simply open the bridge from a regulatory story to a commercial one.

The filings point to a fairly sharp answer. CDX did move beyond a pure approval story. PMA approval in November 2025, Medicare reimbursement, coverage for roughly 142 million insured lives across 39 health plans, and the planned shift from an LDT model to IVD-kit distribution are all real commercial steps. But commercial scale is still not proven. The company itself describes 2026 as a phased launch year for labs, and the investor presentation places IsoPSA test-volume growth within the next 18 months rather than as an already-achieved fact.

That distinction matters. Between approval and scale there is a middle stage: channel buildout. CDX is clearly in that stage now, but that is not the same thing as broad commercial penetration. Even the year-end carrying value says as much: it is still anchored mainly to the latest private financing round from October 2025 rather than to disclosed evidence of scaled market adoption.

What PMA Actually Changed

It would be too simplistic to treat PMA as just another regulatory quality mark. In practice, it changes the route to market. Before approval, CDX was selling IsoPSA mainly as an LDT run through its own CLIA-certified lab. After approval, it gained a different path: marketing and distributing IVD kits to clinical labs in the United States, and potentially beyond, while still keeping the option to run the test through its own lab.

That is a deeper business change than the headline suggests. An LDT model keeps the test tied to the company’s own lab infrastructure. An IVD-kit model allows a service-heavy product to become something that can be distributed outward. So PMA does not just reduce regulatory risk. It materially lifts the ceiling on possible market reach.

But precision matters here too. The commercial door did not suddenly appear only in November 2025. CDX had already signed a non-exclusive distribution agreement with Quest Diagnostics in December 2022 to expand access to the test across the United States. The catch is that the agreement did not include any minimum purchase commitment. In other words, there was already some commercial access before PMA, yet not enough evidence to call it scale. PMA upgrades the channel. It does not automatically settle the adoption question.

That is why the right read is more nuanced. PMA is the moment CDX stopped being primarily a regulatory option and became a real commercialization candidate. It is not yet the moment when the company can clearly be called a scaled commercial diagnostics platform.

Reimbursement Is Broad Enough. The Bottleneck Has Moved to Labs and Physicians

Against the regulatory hurdle that has now been cleared, the reimbursement setup already looks much more mature. Medicare approved $600 reimbursement in 2022, and that amount was updated to $760 in January 2024. Beyond that, by the end of 2025 CDX had expanded coverage to about 142 million insured lives, with IsoPSA covered under 39 separate health plans.

The important point is that the active bottleneck is no longer just coding, coverage, or pricing. Much of that infrastructure is already in place. The bottleneck has moved somewhere else: how many labs will actually run the test, how many physicians will routinely use it in biopsy decisions, and how much of the available coverage base will convert into recurring test volume.

That is exactly where overstatement becomes risky. Broad reimbursement is close to a prerequisite for real commercialization, but it is still not proof of commercialization at scale. It tells you the test can be ordered and reimbursed. It does not yet tell you that the ordering pattern is already deep, repeatable, and economically meaningful.

The company’s own language points to that middle stage. It says the transition toward selling test kits to laboratories is still in its early phases and is expected to happen gradually. When that is the disclosure standard, the clean read is that CDX has reached commercial readiness, but not yet commercial scale.

Even the Bull Case Still Places Scale Ahead

The early-2026 investor presentation frames CDX as a diagnostics platform that has undergone meaningful de-risking: it has PMA approval, commercial traction, and a scalable reagent-based model. That is a bullish framing, and it is not unreasonable. The same presentation also makes clear that most of the last-round portfolio value discussed there relates to CDX.

But this is also where the most important clue sits. The presentation does not describe scale as something already achieved. Instead, it places continued growth in IsoPSA test volumes following PMA approval inside the next 18 months. That is a material distinction. If even the most optimistic framing still treats volume growth and channel expansion as forward milestones, it is hard to argue that CDX has already crossed the scale threshold.

The 2026 operating plan says the same thing in a more formal way: phased launch into reference labs, commercial labs, and hospitals, starting with a pilot-lab rollout and then expanding gradually. At the same time, CDX is expected to run a Post-Approval Study, publish additional clinical data, and continue developing further platform applications. That is the profile of a MedTech company entering commercialization. It is not yet the profile of a product that has already locked in wide market adoption.

What the Carrying Value Already Assumes, and What It Still Does Not

The valuation work helps put the trajectory in proportion. According to the attached valuation report, the fair value of Merchavia’s CDX holding stood at $3.443 million at the end of 2024, stayed at $3.443 million as of June 30, 2025, and rose to $3.805 million at year-end 2025.

That increase matters, but the anchor matters at least as much. The valuation report explicitly says the most recent investment round is the best observable basis for fair value. The annual report says the December 31, 2025 valuation was derived from the October 2025 financing round, in which CDX raised roughly $14 million. So even after PMA approval, the accounting value is still driven mainly by a private-market financing reference point, not by disclosed evidence of scaled commercial demand.

The income statement tells a similar story. The reporting period included only about NIS 79 thousand of fair-value gain on the CDX investment, while foreign-exchange movement produced a loss of about NIS 1.604 million. In other words, year-end 2025 does not yet show the kind of accounting step-up that would signal a commercialization proof point already established in the market. It shows that the private market is still willing to fund the story, and that the regulatory event improved its quality. That is not the same thing as volume proof.

This is where the next validation point for Merchavia now sits. If approval, reimbursement, and the new channel structure are at least partly embedded in the story already, the next real move will not come from another regulatory label. It will come from evidence of adoption: more labs, more physicians, more tests, and commercial agreements that carry substance beyond simply opening a door.

Bottom Line

CDX did move from a regulatory threshold into a commercial phase. Denying that would be too conservative. PMA approval, Medicare reimbursement, broader payer coverage, and the planned move into IVD-kit distribution all changed the company’s starting point in a meaningful way.

But calling it commercial scale already would still go one step too far. The 2026 plan, the investor presentation, and the way year-end value is measured all point in the same direction: CDX has moved from approval into execution, not from execution into proof.

For Merchavia, that distinction is crucial. When the central asset in the portfolio carries most of the visible value, the question is no longer whether approval exists. The question is whether approval is beginning to turn into repeatable adoption, measurable usage, and eventually value that can be defended not only by a private financing round but by real commercialization. Until then, CDX is a better asset than it was a year ago, but it is still not a fully mature commercial asset in the strict sense.